Congratulations to Brad Kossmann who published a new paper in the journal Bioorganic & Medicinal Chemistry Letters entitled “Discovery of selective inhibitors of tyrosyl-DNA phosphodiesterase 2 by targeting the enzyme DNA-binding cleft”. The paper details the characterization of three new selective inhibitors of the enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2). TDP2processes protein/DNA adducts resulting from abortive DNA topoisomerase II (Top2) activity. TDP2 inhibition could therefore provide synergism with the Top2 poison class of chemotherapeutics.